Login to Your Account



Threshold Dives On Lack Of Efficacy In BPH Trials

By Jennifer Boggs


Tuesday, July 18, 2006
Shares of Threshold Pharmaceuticals Inc. lost more than half their value after the company said it was dropping its benign prostatic hyperplasia drug, TH-070, following misses in Phase II and Phase III studies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription